Genentech Inc - Strategic SWOT Analysis Review
Description
Genentech Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
Genentech Inc (Genentech), a subsidiary of Roche Holding AG, is a biotechnology company that discovers, develops, manufactures, and commercializes medicines for serious and life-threatening diseases. It offers drugs in various therapeutic areas, including oncology, infectious disease, immunology, ophthalmology, neurology, metabolism, primary care, and specialty care. Genentech also offers patient support services such as co-pay programs, health insurance, and independent co-pay assistance, among others. The company's products are offered to patients with complex health conditions mainly in the US healthcare market. It operates a manufacturing facility in the US. Genentech is headquartered in South San Francisco, California, the US.
Genentech Inc Key Recent Developments
May 19,2026: Genentech To Present New Data at ASCO 2026, Reinforcing Giredestrant’s Potential To Transform the Treatment Paradigm in Early Breast Cancer
May 15,2026: FDA Approves Genentech Tecentriq as Adjuvant ctDNA-Guided Treatment for Muscle-Invasive Bladder Cancer
Apr 22,2026: Genentech’s Fenebrutinib Reduces Relapses to About One Every 17 Years in RMS
Mar 02,2026: Genentech's Fenebrutinib Demonstrates Efficacy in Relapsing and Primary Progressive MS in FENhance 1
Reasons to Buy
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
Genentech Inc (Genentech), a subsidiary of Roche Holding AG, is a biotechnology company that discovers, develops, manufactures, and commercializes medicines for serious and life-threatening diseases. It offers drugs in various therapeutic areas, including oncology, infectious disease, immunology, ophthalmology, neurology, metabolism, primary care, and specialty care. Genentech also offers patient support services such as co-pay programs, health insurance, and independent co-pay assistance, among others. The company's products are offered to patients with complex health conditions mainly in the US healthcare market. It operates a manufacturing facility in the US. Genentech is headquartered in South San Francisco, California, the US.
Genentech Inc Key Recent Developments
May 19,2026: Genentech To Present New Data at ASCO 2026, Reinforcing Giredestrant’s Potential To Transform the Treatment Paradigm in Early Breast Cancer
May 15,2026: FDA Approves Genentech Tecentriq as Adjuvant ctDNA-Guided Treatment for Muscle-Invasive Bladder Cancer
Apr 22,2026: Genentech’s Fenebrutinib Reduces Relapses to About One Every 17 Years in RMS
Mar 02,2026: Genentech's Fenebrutinib Demonstrates Efficacy in Relapsing and Primary Progressive MS in FENhance 1
Reasons to Buy
- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Table of Contents
51 Pages
- List of Tables
- List of Figures
- Section 1 - About the Company
- Genentech Inc - Key Facts
- Genentech Inc - Key Employees
- Genentech Inc - Major Products and Services
- Genentech Inc - History
- Genentech Inc - Locations And Subsidiaries
- Head Office
- Section 2 – Company Analysis
- Company Overview
- Genentech Inc - Business Description
- R&D Overview
- Genentech Inc - SWOT Analysis
- SWOT Analysis - Overview
- Genentech Inc - Strengths
- Genentech Inc - Weaknesses
- Genentech Inc - Opportunities
- Genentech Inc - Threats
- Genentech Inc - Key Competitors
- Section 3 – Company’s Lifesciences Financial Deals and Alliances
- Genentech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
- Genentech Inc, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
- Genentech Inc, Recent Deals Summary
- Section 4 – Company’s Recent Developments
- May 19, 2026: Genentech To Present New Data at ASCO 2026, Reinforcing Giredestrant’s Potential To Transform the Treatment Paradigm in Early Breast Cancer
- May 15, 2026: FDA Approves Genentech Tecentriq as Adjuvant ctDNA-Guided Treatment for Muscle-Invasive Bladder Cancer
- Apr 22, 2026: Genentech’s Fenebrutinib Reduces Relapses to About One Every 17 Years in RMS
- Mar 02, 2026: Genentech's Fenebrutinib Demonstrates Efficacy in Relapsing and Primary Progressive MS in FENhance 1
- Feb 20, 2026: FDA Accepts New Drug Application for Genentech's Giredestrant in ESR1-Mutated, ER-Positive Advanced Breast Cancer
- Feb 04, 2026: Genentech Awards Grant To Support Science Center’s Translation Project
- Feb 03, 2026: SanegeneBio and Genentech sign $1.5bn global RNAi licensing deal
- Jan 20, 2026: Genentech More than Doubles Investment in Holly Springs, North Carolina Manufacturing Facility
- Dec 19, 2025: Genentech Announces Agreement With U.S. Government
- Dec 19, 2025: President Donald J. Trump Announces Largest Developments to Date in Bringing Most-Favored-Nation Pricing to American Patients
- Section 5 – Appendix
- Methodology
- About GlobalData
- Contact Us
- Disclaimer
- List of Tables
- Genentech Inc, Key Facts
- Genentech Inc, Key Employees
- Genentech Inc, Major Products and Services
- Genentech Inc, History
- Genentech Inc, Key Competitors
- Genentech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
- Genentech Inc, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
- Genentech Inc, Recent Deals Summary
- List of Figures
- Genentech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
- Genentech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

